Modulation of Autophagy is a Potential Strategy for Enhancing the Anti-Tumor Effect of Mebendazole in Glioblastoma Cells

Seong Bin Jo¹²³†, So Jung Sung¹²³†, Hong Seok Choi¹²³, Jae-Sung Park⁴, Yong-Kil Hong⁵ and Young Ae Joe¹²³*  
¹Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, ²Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Seoul 06591, ³Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, ⁴Department of Neurosurgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, ⁵Department of Neurosurgery, Hallym University Sacred Heart Hospital, Anyang 14068, Republic of Korea

Abstract
Mebendazole (MBZ), a microtubule depolymerizing drug commonly used for the treatment of helminthic infections, has been suggested as a repositioning candidate for the treatment of brain tumors. However, the efficacy of MBZ needs further study to improve the beneficial effect on the survival of those patients. In this study, we explored a novel strategy to improve MBZ efficacy using a drug combination. When glioblastoma cells were treated with MBZ, cell proliferation was dose-dependently inhibited with an IC₅₀ of less than 1 µM. MBZ treatment also inhibited glioblastoma cell migration with an IC₅₀ of less than 3 µM in the Boyden chamber migration assay. MBZ induced G2-M cell cycle arrest in U87 and U373 cells within 24 h. Then, at 72 h of treatment, it mainly caused cell death in U87 cells with an increased sub-G1 fraction, whereas polyploidy was seen in U373 cells. However, MBZ treatment did not affect ERK1/2 activation stimulated by growth factors. The marked induction of autophagy by MBZ was observed, without any increased expression of autophagy-related genes ATG5/7 and Beclin 1. Co-treatment with MBZ and the autophagy inhibitor chloroquine (CQ) markedly enhanced the anti-proliferative effects of MBZ in the cells. Triple combination treatment with temozolomide (TMZ) (another autophagy inducer) further enhanced the anti-proliferative effect of MBZ and CQ. The combination of MBZ and CQ also showed an enhanced effect in TMZ-resistant glioblastoma cells. Therefore, we suggest that the modulation of protective autophagy could be an efficient strategy for enhancing the anti-tumor efficacy of MBZ in glioblastoma cells.

Key Words: Mebendazole, Autophagy, Autophagy inhibitor, Chloroquine, Glioblastoma

INTRODUCTION
Glioblastoma is the most aggressive incurable adult brain tumor, accounting for about 60% of adult brain tumors (Wu et al., 2021). The average 5-year patient survival rate is 7.2%. Despite the development of novel therapies and techniques, little improvement in overall survival (OS) has been achieved, partly due to limited anti-cancer drug penetration through the blood-brain barrier (BBB). Surgery is the most effective treatment for glioblastoma patients, and radiotherapy (RT) is the most accepted adjuvant therapy (Veliz et al., 2015). Temozolomide (TMZ) has been used as the first-choice chemotherapeutic agent for glioblastoma treatment, since it replaced the PCV regimen [a combination of procarbazine, 1-(2-chloroethyl)-3-cy-clohexyl-1-nitrosourea (CCNU), and vincristine] in 2005 (Stupp et al., 2005). When combined with RT, TMZ showed weaker side effects and greater efficacy compared to PCV. However, the current standard of care using TMZ and RT for glioblastoma still leads to poor prognosis with a median OS of 14.6 months. Thus, many efforts have been made to identify TMZ adjuvants or substitutes, but no promising drugs have been found for curing glioblastoma patients.

Mebendazole (MBZ), a benzimidazole derivative, is widely used as an anthelmintic drug along with albendazole and acts as a microtubule-disrupting agent by binding to the colchicine-binding domain of tubulin (Friedman and Platzer, 1980, Laclette et al., 1980). The cytotoxic effect of MBZ has been reported in several cancer cells such as melanoma, gastric, and...
Autophagy is the process of constant degradation of damaged or superfluous proteins and organelles under several stressful conditions. During this process, double-membrane vesicles termed autophagosomes, form, engulf damaged protein aggregates and organelles, and then fuse with lysosomes to recycle the components (Choi et al., 2013a). The formation of autophagosomes is initiated by class III PI3K and Beclin 1. Autophagy-related gene 5 (ATG5) and autophagy-related gene 7 (ATG7) are involved as core proteins in the process. Autophagy plays a dual role in tumor suppression and promotion and regulates the stemness of cancer stem cells, tumor recurrence, and resistance to anticancer agents (Yun and Lee 2018; Shin, 2020). Autophagy is activated in tumor cells by chemotherapeutic agents and radiation and serves to protect the tumor cells (Paglin et al., 2001; Kanzawa et al., 2004; Sui et al., 2013). Thus, targeting autophagy has emerged as a promising strategy to enhance anti-cancer efficacy and overcome tumor resistance to various cancer treatments (Xiao et al., 2021).

Previously, we reported that MBZ induced autophagy in endothelial cells, and inhibited endothelial proliferation, migration, and tube formation (Sung et al., 2019). Autophagy inhibition by siRNAs against Beclin 1 or ATG 5/7 and the autophagy inhibitor chloroquine (CQ) enhanced the anti-proliferative and pro-apoptotic effects of MBZ in endothelial cells. CQ (weakly basic) is widely known as an antimalarial drug and increases intracellular pH by accumulating in acidic lysosomes, preventing the fusion of autophagosomes with lysosomes, and inhibiting the late stage of autophagy (Poole and Ohkuma, 1981). In glioblastoma patients, the addition of CQ to glioblastoma standard therapy was shown to exert a beneficial adjuvant effect (Briceno et al., 2007). Therefore, in this study, we evaluated the efficacy of the combination of MBZ and CQ in glioblastoma cells as a novel treatment option.

MATERIALS AND METHODS

Reagents

Mebendazole (MBZ), chloroquine (CQ), and temozolomide (TMZ) were purchased from Sigma (St. Louis, MO, USA). MBZ and TMZ were dissolved in dimethyl sulfoxide (DMSO). CQ diphosphate was dissolved in phosphate-buffered saline (PBS).

Cell culture

Human glioblastoma cell lines, U87-MG and LN18 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). U373 and T98G cells were purchased from the Korean Cell Line Bank (KCLB, Seoul, Korea). To obtain TMZ-resistant cells, U87-MG and U373 cell lines were initially cultured in the presence of 25 µM TMZ. The concentration was then increased by 2-fold at every two passages until it reached 800 µM. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, WelGENE Inc., Daegu, Korea) supplemented with 10% fetal bovine serum (FBS, Corning, NY, USA) and 1% antibiotics under standard culture conditions of 5% CO2 and 37°C.

Cell viability assay

The cells were seeded at 1×10^4 cells per well in 96-well plates. After 24 h, fresh medium with or without inhibitor was added and cultured for 48-72 h. For combination treatment, 1×10^3 cells were seeded in a 96-well plate. After 24 h, the cells were treated with 50 µM TMZ and 0.2 µM MBZ, incubated for 24 h, and then treated with 20 µM CQ and incubated for 48 h. Cell proliferation was assessed using the MTS Cell Viability Assay Kit (Promega Corp., Madison, WI, USA). MTS reagent (20 µL) was added to each well. After 2 h, the plates were read at 490 nm using an ELISA plate reader.

Cell migration assay

The cell migration assay was performed in a modified Boyden chamber as described previously (Kim et al., 2008). Serum-starved U87 and U373 cells were incubated with MBZ for 30 min and then seeded into the upper chamber (2×10^4 cells). DMEM containing 10% FBS was added to the lower chamber. Cell migration was allowed for 24 h, and then the migrated cells were fixed and stained with Diff-Quik solution (Sysmex Co., Kobe, Japan). The migrated cells were photographed and counted in five randomly selected fields.

Cell cycle analysis

U87 and U373 cells were cultured for 24 h, serum-starved for 4 h, and then treated with MBZ (0, 1, and 3 µM) for 24, 48, and 72 h. The cells were collected after trypsin-EDTA treatment, washed with PBS, and fixed with 70% ethanol overnight at −20°C. After centrifugation, the cells were resuspended in 1 mL of a hypotonic solution containing 50 µg/mL of propidium iodide (PI), 0.1% sodium citrate, 0.1% Triton X-100, and 10 µg/mL of RNase and incubated in the dark at room temperature for 30 min. PI fluorescence was measured on a linear scale using a FACScan flow cytometer (FACS Canto II, BD Biosciences, NJ, USA), and cell cycle distribution was analyzed using FlowJo software (TreeStar, Ashland, OR, USA).

DAPI staining to visualize apoptosis

To investigate apoptosis after MBZ treatment, the cells were stained with fluorescent 4’,6-diamidino-2-phenylindole (DAPI) to detect nuclear condensation and chromatin fragmentation. U87 and U373 cells grown on coverslips were treated with MBZ for 72 h and fixed with 4% paraformaldehyde (PFA) for 10 min. The fixed cells were stained with 1 µg/mL of DAPI solution (Sigma) for 10 min and examined under fluorescence microscope (Observer Z1 inverted, ZEISS, Oberkochen, Germany). The percentage of apoptotic cells was calculated as the number of cells with apoptotic nuclei divided by the total number of cells in three random fields.

Western blot analysis

Western blotting was performed as described previously.
Mebendazole inhibits the proliferation and migration of glioblastoma cells. (A) Glioblastoma cells (U87, U373, T98G, and LN18) were treated with the indicated concentrations of MBZ. After 48 h, the MTS assay was performed (left panel). The percentage of proliferation was calculated based on the cell proliferation of the untreated control group. U87 and U373 cells were treated with MBZ (1 and 3 µM) for 24 h and then observed by light microscopy (right panel). Scale bars: 100 µm. (B) Glioblastoma cells (U87, U373, T98G, and LN18) pretreated with the indicated concentrations of MBZ for 30 min were allowed to migrate into the bottom chamber with medium containing 10% FBS for 24 h. Then, the migrated cells were counted per view field. **p<0.01 and ***p<0.001.

Data and statistical analysis

All experiments were repeated three times, and statistical values were presented as means ± standard error of the mean (SEM) of representative experiments. Differences between groups were analyzed by student’s t-test for comparison of two groups and one-way ANOVA with Turkey test for comparison of three or more groups using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) for most experiments. p-values less than 0.05 were considered as statistically significant.

RESULTS

Mebendazole inhibits the proliferation and migration of glioblastoma cells

We investigated whether MBZ inhibited the proliferation of human glioblastoma cells under growth conditions. We tested U87, U373, T98G, and LN18 glioblastoma cell lines with different molecular backgrounds. As shown in Fig. 1A, all of the cells tested showed a dose-dependent inhibition of cell proliferation with IC50 values of 0.22-0.65 µM. Treatment with 1 µM MBZ led to cell shrinkage at 24 h in both U87 and U373 cells, due to its anti-microtubule action. Upon MBZ treatment, the cells shrunk, aggregated, or floated in the culture media. Next, we performed a modified Boyden chamber assay to examine whether MBZ inhibited the migration of glioblastoma cells. As shown in Fig. 1B, MBZ significantly inhibited 10% FBS-induced glioblastoma cell migration in a dose-dependent man-
Overall, the effect of MBZ to inhibit migration (IC$_{50}$ = 0.88-2.25 µM) was less than its effect to inhibit proliferation. Thus, these results suggest that MBZ inhibits the proliferation and migration similarly in all the types of glioblastoma cells.

**Mebendazole induces G2-M arrest and apoptosis in glioblastoma cells**

Since anti-microtubule agents induce G2-M cell cycle arrest and apoptosis (Kaur et al., 2014), we examined whether MBZ affected cell cycle progression in glioblastoma cells. U87 and U373 cells were treated with MBZ (1 and 3 µM) for 24, 48, and 72 h prior to DAPI staining and FACS analysis. An increase in G2-M arrest was observed in MBZ-treated U87 and U373 cells at 24 h (Fig. 2A, 2B). Then, the number of polyploid cells and cells in the sub-G1 fraction was increased over time from 24 h to 72 h. Treatment with 1 µM MBZ caused marked apoptosis in U87 cells (16.6% at 72 h), whereas few apoptotic U373 cells were seen at 1 µM MBZ treatment (3.1% at 72 h). Apoptosis
Mebendazole induces autophagy in glioblastoma cells

Previously, MBZ was reported to interfere with vascular endothelial growth factor (VEGF) receptor 2 (VEGFR2) by competing with ATP (IC50 = 4.3 μM), thereby inhibiting the autophosphorylation of the Y1175 residue (Bai et al., 2015a). This site provides a binding site for phospholipase C gamma (PLCγ), eventually leading to the phosphorylation of ERK1/2 (Takahashi et al., 2001). Thus, there is a possibility that MBZ could also interfere with growth factor-induced signaling pathways by competing with ATP. Therefore, we examined whether MBZ could inhibit growth factor-induced ERK activation. In the experiment, we used a relatively high dose of MBZ to treat glioblastoma cells prior to growth factor stimulation. As shown in Fig. 3A, no significant inhibition of ERK activation was observed after bFGF stimulation in U87 cells pre-treated with 10 μM MBZ for 1 h. A similar pattern was observed in U373 cells pre-treated with MBZ (Fig. 3B). No change in phospho-ERK1/2 levels was observed when the cells were treated with 10 μM MBZ for a longer time (24 h) under culture conditions containing 10% FBS. Therefore, the results indicate that MBZ has no effect on the growth factor-stimulated ERK1/2 signaling pathway in glioblastoma cells.

Mebendazole induces autophagy in glioblastoma cells

Benzimidazole drugs, flubendazole and albendazole, have been reported to induce autophagy in tumor cells (Zhang et al., 2015, Jung et al., 2022). Previously, we also demonstrated that MBZ increased LC3-positive puncta and LC3B-II/LC3B-I ratios in human umbilical vein endothelial cells time- and dose-dependently (Sung et al., 2019). Here, we examined whether MBZ induced autophagy in glioblastoma cells. Western blot analysis of MBZ-treated U87 and U373 cells showed a dose-dependent increase in the LC3B-II/LC3B-I ratio (Fig. 4). When the expression level of Beclin 1, the main regulator of autophagy initiation, was examined by Western blot analysis, we found that MBZ treatment had no effect on Beclin 1 expression. The expression of ATG5 and ATG7, core proteins involved in autophagosome formation, was also not affected by MBZ treatment. Thus, the results indicate that MBZ induces autophagy in glioblastoma cells without upregulating autophagosome formation-related proteins.
Effect of the triple combination of TMZ, MBZ, and CQ on U87 and U373 cells

Previously, we demonstrated the synergistic efficacy of the combination of TMZ (autophagy inducer) and CQ (late-stage autophagy inhibitor) in glioblastoma cells (Lee et al., 2015). Thus, we were interested in whether the inhibitory efficacy of autophagy-inducing MBZ could be enhanced by CQ in glioblastoma cells. Indeed, the inhibition of proliferation was enhanced by the combination of MBZ and CQ in U87 cells (data not shown). A previous preclinical model study showed that the combination of MBZ and TMZ extended survival further than TMZ treatment alone (Bai et al., 2011). The main inhibitory mechanism of TMZ (DNA-alkylating agent) is different from that of MBZ, and both drugs induce autophagy. Thus, we can expect improved efficacy when TMZ and MBZ are combined with late-stage autophagy inhibitors. Therefore, we examined the efficacy of the triple combination of TMZ, MBZ, and CQ as a novel therapy to improve the efficacy of standard therapy in glioblastoma patients. As shown in Fig. 5A, in U87 cells, the combination of MBZ and CQ or TMZ and CQ significantly decreased proliferation compared to single treatments alone. The highest inhibition was achieved by the triple combination. In the Western blot assessment of autophagy, all cells co-treated with CQ showed a marked increase in the LC3B-II/LC3B-I ratio, whereas single treatment with TMZ or MBZ showed lower conversion of LC3B-II to LC3B-I. In U373 cells, the addition of CQ to MBZ or TMZ treatment also showed an enhanced inhibitory effect compared to MBZ or TMZ treatment alone (Fig. 5B). The triple combination treatment also showed better outcomes than double combination treatments in U373 cells. Accordingly, high conversion of LC3B-II to LC3B-I was observed in the triple combination treatment. The results indicate that the triple combination of TMZ, MBZ, and CQ is highly effective in inhibiting TMZ-sensitive glioblastoma cell growth.

Inhibition of TMZ-resistant glioblastoma cell growth by the combination of MBZ and CQ

At present, TMZ is the first-choice chemotherapeutic agent to cure glioblastoma. However, glioblastoma develops resistance to TMZ through pathways such as O6-methylguanine methyltransferase (MGMT), alkylpurine-DNA-N-glycosylase (APNG), base excision repair (BER), and others (Zhang et al., 2012; Singh et al., 2021). Thus, we tested whether the combination of MBZ and CQ could be an effective treatment to overcome TMZ resistance. First, we obtained TMZ-resistant cells (IC50≥400 µM) by culturing U87 and U373 cells in the presence of gradually increasing concentrations of TMZ for more than one month (Fig. 6A, left panel). When the TMZ-resistant cells were treated with MBZ alone, the treated cells showed a dose-dependent inhibitory effect on cell proliferation at levels (IC50=0.3-0.58 µM) similar to those of TMZ-sensitive U87 and U373 cells (Fig. 6A, right panel). Furthermore, the combination of MBZ and CQ showed enhanced anti-proliferative effects in the TMZ-resistant cells (Fig. 6B). Thus, these results suggest that the combination of MBZ and CQ is effective in inhibiting the proliferation of TMZ-resistant cells.

DISCUSSION

Benzimidazole anti-helminthics can exert cytotoxicity by binding to nematode tubulin molecules at low concentrations, thereby inhibiting tubulin polymerization and microtubule formation in a fashion similar to that of colchicine (Friedman and Plätzer, 1980; Lacey, 1988). MBZ also inhibited tubulin polymerization at 1 µM in human glioblastoma cells and elicited in vivo anti-tumor effects in preclinical glioblastoma animal models (Bai et al., 2011). MBZ can be an attractive adjuvant candidate for TMZ because MBZ has good BBB penetration. In the present study, we found that MBZ induced autophagy in glioblastoma cells and that combined treatment with MBZ and CQ increased the anti-proliferative effects on glioblastoma cells, like the synergistic effect of combined TMZ and CQ treatment (Lee et al., 2015). We also found that when combined with TMZ, a standard therapeutic agent for glioblastoma, the inhibitory effect of the combination of MBZ and CQ was enhanced. Notably, we demonstrated that the MBZ and CQ combination could provide an effective treatment for TMZ-resistant glioblastoma.

Despite many efforts, glioblastoma is still an incurable dis-
ease with an extremely poor patient prognosis and a median overall survival of 14.6 months, even in patients who receive standard therapy (surgery+TMZ+RT) (Stupp et al., 2005). TMZ is the first-choice chemotherapeutic agent with significant survival benefits in glioblastoma patients (Stupp et al., 2009). Autophagy is noted as a resistance mechanism of TMZ in glioblastoma cells since autophagy induced by TMZ treatment functions as a survival and protective mechanism (Sui et al., 2009). Since glioblastoma cells do not express VEGFR2, we were not able to assess the ability of MBZ to inhibit VEGFR2. However, it is possible that MBZ could also compete with ATP for other receptor kinases. We were also interested in whether or not TMZ resistance. In the case of patients sensitive to TMZ, a triple combination could achieve the best outcome.

Since glioblastoma cells do not express VEGFR2, we were not able to assess the ability of MBZ to inhibit VEGFR2. However, it is possible that MBZ could also compete with ATP for other receptor kinases. We were also interested in whether MBZ treatment may increase the autophagic flux in glioblastoma cells. Notably, these genes were not included in the reported prognostic autophagy biomarkers. In the future, it will be interesting to determine whether the expression of these autophagy biomarkers is correlated with MBZ sensitivity.

To enhance the anti-tumor effect of autophagy-inducing chemotherapeutics, CQ, a late-stage autophagy inhibitor, has been applied in pre-clinical and clinical studies. The inhibition of autophagy by CQ has been reported to enhance the cytotoxic effects of both RT and chemotherapy (Golden et al., 2014; Hori et al., 2015), and a recent clinical study also showed favorable toxicity and promising OS from treatment with CQ combined with TMZ and RT (Compper et al., 2021). Previously, we reported the synergistic effect of the combination of TMZ and CQ (Lee et al., 2015). In this study, we showed autophagy induction by MBZ and the increased efficacy of combined MBZ and CQ treatment. We also provided evidence that the triple combination of TMZ, MBZ, and CQ produced the greatest inhibition of tumor cell proliferation. Furthermore, we found that the combination of MBZ and CQ was effective in inhibiting TMZ-resistant cell proliferation. Although autophagy induction is a resistance mechanism against chemotherapy, CQ seems to enable cells to overcome drug resistance by inhibiting late-stage autophagy. Targeting autophagy against drug resistance has also been shown in several cases, including the effectiveness of CQ treatment in imatinib-resistant chronic myeloid leukemia (Bellodi et al., 2009; Chang and Zou, 2020). Therefore, we could suggest that the combination of MBZ and CQ would be a good strategy for treating glioblastoma patients with or without TMZ resistance. In the case of patients sensitive to TMZ, a triple combination could achieve the best outcome.

Since glioblastoma cells do not express VEGFR2, we were not able to assess the ability of MBZ to inhibit VEGFR2. However, it is possible that MBZ could also compete with ATP for other receptor kinases. We were also interested in whether MBZ could inhibit growth-factor-mediating signaling through other mechanisms. In this study, we found that MBZ caused G2-M arrest by disrupting microtubule polymerization but did not inhibit growth factor-mediated ERK1/2 signaling pathways.
The IC50 of MBZ for inhibiting VEGFR2 is hardly achievable at clinical doses (Munst et al., 1980). Thus, the inhibitory mechanism of MBZ may not be related to growth factor-mediating signaling.

Glioblastoma is not curable due to genetic heterogeneity and the restricted passage of drugs through the BBB (Wu et al., 2021). However, MBZ induces autophagy, penetrates the BBB, and demonstrates favorable toxicities. Its inhibitory activity is derived from tubulin binding rather than the specific inhibition of signaling, suggesting that it can evade the development of drug-specific resistance in genetically heterogeneous glioblastoma. Thus, adding MBZ to standard therapy will benefit glioblastoma patients. In addition, MBZ in combination with autophagy inhibitors could provide a solution to overcome TMZ/R不少 resistance. In the future, more potent and less toxic autophagy inhibitors are anticipated for combination with MBZ to effectively cure glioblastoma.

CONFLICT OF INTEREST

The authors have no competing interests to declare.

ACKNOWLEDGMENTS

This research was supported by grants from the National Research Foundation of Korea grants funded by the Korean government (NRF-2012R1A5A2047939, NRF-2020R1A2C2006189).

REFERENCES

Bai, R. Y., Staedtke, V., Aphys, C. M., Gallia, G. L. and Riggins, G. J. (2011) Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. *Neuro Oncol.* **13**, 974-982.

Bai, R. Y., Staedtke, V., Rudin, C. M., Bunz, F. and Riggins, G. J. (2015a) Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. *Neuro Oncol.* **17**, 545-554.

Bai, R. Y., Staedtke, V., Wanjiku, T., Rudek, M. A., Ackermans, L., Beckvordersanft, J., Bauer, N. J. C., Anten, M. M., Wesseling, P., Postma, A. A., De Ruyscher, D. and Lamfin, P. (2021) Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase Ib trial. *Autoimmunity* **54**, 2604-2612.

De Witt, M., Ramble, A., Hansson, D., Markowitz, D., Powell, C., Al Dimassi, S., Atlas, M., Bockckav, J., Ruggieri, R. and Symons, M. (2017) Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. *Mol. Med.* **23**, 50-56.

Doudican, N., Rodriguez, A., Osman, I. and Orlow, S. J. (2008) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. *Mol. Cancer Res.* **6**, 1308-1315.

Friedman, P. A. and Platzer, E. G. (1980) Interaction of anthelmintic benzimidazoles with Ascaris suum embryonic tubulin. *Biochim. Biophys. Acta, Gen. Subj.* **630**, 271-278.

Golden, E. B., Cho, H. Y., Jahanian, A., Hofman, F. M., Louie, S. G., Schonthal, A. H. and Chen, T. C. (2014) Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. *Neurosurg. Focus* **37**, E12.

Horii, Y. S., Hosoda, R., Akiyama, Y., Seboshi, R., Waniwuchi, M., Mikami, T., Sugino, T., Suzuki, K., Maruyama, Y., Tsukamoto, M., Miki, N., Hori, Y. and Kuno, A. (2015) Chloroquine potentiates temozolomide cytotoxicity by inhibiting mitochondrial autophagy in glioma cells. *J. Neurooncol.* **122**, 11-20.

Jung, Y. Y., Baek, S. H., Ha, I. J. and Ahn, K. S. (2022) Regulation of apoptosis and autophagy by albendazole in human colon adenocarcinoma cells. *Biochimie* **198**, 155-166.

Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y. and Kondo, S. (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. *Cell Death Differ.* **11**, 448-457.

Kaur, R., Kaur, G., Gill, R. K., Soni, R. and Bartwal, J. (2014) Recent developments in tubulin polymerization inhibitors: an overview. *Eur. J. Med. Chem.* **87**, 89-124.

Kim, H. K., Oh, D. S., Lee, S. B., Ha, J. M. and Joe, Y. A. (2008) Antimigratory effect of TK1-2 is mediated in part by interfering with integrin alpha2beta1. *Mol. Cancer Ther.* **7**, 2123-2141.

Lacey, E. (1988) The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. *Int. J. Parasitol.* **18**, 885-936.

Lachette, J. P., Guerra, G. and Zetina, C. (1980) Inhibition of tubulin polymerization by Mebendazole. *Biochem. Biophys. Res. Commun.* **92**, 417-423.

Lee, S. W., Kim, H. K., Lee, N. H., Yi, H. Y., Kim, H. S., Hong, S. H., Hong, Y. K. and Joe, Y. A. (2015) The synergistic effect of combination temozolomide and chloroquine treatment is dependent on autophagy formation and p53 status in glioma cells. *Cancer Lett.* **360**, 195-204.

Mukhopadhayay, T., Sasaki, J., Ramesh, R. and Roth, J. A. (2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. *Clin. Cancer Res.* **8**, 2963-2969.

Munst, G. J., Karlaganis, G. and Bircher, J. (1980) Plasma concentration of mebendazole during treatment of echinococcosis: preliminary results. *Eur. J. Clin. Pharmacol.* **17**, 375-378.

Paplin, S., Hollister, T., Delohery, T., Hackett, N., McMahl, M., Spica, E., Domingo, D. and Yahalom, J. (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. *Cancer Res.* **61**, 439-449.

Pantziarka, P., Bouge, G., Meheus, L., Sukhatme, V. and Sukhatme, V. P. (2014) Repurposing Drugs in Oncology (ReDo)-mebendazole as an anti-cancer agent. *Ecancermedicalscience* **8**, 443.

Pinto, L. C., Soares, B. M., Pinheiro Jde, J., Riggins, G. J., Assumpcao, P. P., Burbano, R. M. and Montenegro, R. C. (2015) The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model. *Toxicol. In Vitro* **29**, 2038-2044.

Pood, B. and Ohkuma, S. (1981) Effect of weak bases on the intracellular pH in mouse peritoneal macrophages. *J. Cell Biol.* **90**, 665-669.

Shin, D. W. (2020) Dual roles of autophagy and their potential drugs for gliogenic features of Wharton's jelly-derived mesenchymal stromal stem cells and their ability to form functional vessels. *Int. J. Biochem. Cell Biol.* **45**, 560-570.

Compter, I., Eeekers, D. B. P., Hoeven, A., Roushop, K. M. A., Reynen, B., Ackermans, L., Beckvordersanft, J., Bauer, N. J. C., Anten, M. M., Wesseling, P., Postma, A. A., De Ruyscher, D. and Lamfin, P. (2021) Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase Ib trial. *Autoimmunity* **54**, 2604-2612.
improving cancer therapeutics. Biol. Ther. (Seoul) 28, 503-511.
Singh, N., Miner, A., Hennis, L. and Mittal, S. (2021) Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 4, 17-43.
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., Hau, P., Brandes, A. A., Gijsenbeek, J., Marosi, C., Vecht, C. J., Mohktari, K., Wesseling, P., Villa, S., Eisenhauer, E., Gorlia, T., Weller, M., Lacombe, D., Cairncross, J. G. and Mirimanoff, R. O.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466.
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R. C., Ludwin, S. K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J. G., Eisenhauer, E. and Mirimanoff, R. O.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., Han, W., Lou, F., Yang, J., Zhang, Q., Wang, X., He, C. and Pan, H. (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis. 4, e838.
Sung, S. J., Kim, H. K., Hong, Y. K. and Joe, Y. A. (2019) Autophagy is a potential target for enhancing the anti-angiogenic effect of mebendazole in endothelial cells. Biomol. Ther. (Seoul) 27, 117-125.
Takahashi, T., Yamaguchi, S., Chida, K. and Shibuya, M. (2001) A single autophosphorylation site on KDR/Flik-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 20, 2768-2778.
Veliz, J., Loo, Y., Castillo, O., Karachaliou, N., Nigro, O. and Rosell, R. (2015) Advances and challenges in the molecular biology and treatment of glioblastoma—is there any hope for the future? Ann. Transl. Med. 3, 7.
Wang, Y., Zhao, W., Xiao, Z., Guan, G., Liu, X. and Zhuang, M. (2020) A risk signature with four autophagy-related genes for predicting survival of glioblastoma multiforme. J. Cell. Mol. Med. 24, 3807-3821.
Wang, Z., Gao, L., Guo, X., Feng, C., Lian, W., Deng, K. and Xing, B. (2019) Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma. Aging 11, 12246-12269.
Wu, W., Klockow, J. L., Zhang, M., Laforteune, F., Chang, E., Jin, L., Wu, Y. and Daldrup-Link, H. E. (2021) Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol. Res. 171, 105780.
Xiao, M., Benoit, A., Hasmim, M., Duhem, C., Vogin, G., Berchem, G., Noman, M. Z. and Janji, B. (2021) Targeting cytoprotective autophagy to enhance anticancer therapies. Front. Oncol. 11, 626309.
Yun, C. W. and Lee, S. H. (2018) The roles of autophagy in cancer. Int. J. Mol. Sci. 19, 3466.
Zhang, H., Lu, X., Wang, N., Wang, J., Cao, Y., Wang, T., Zhou, X., Jiao, Y., Yang, L., Wang, X., Cong, L., Li, J., Li, J., Ma, H. P., Pan, Y., Ning, S. and Wang, L. (2017) Autophagy-related gene expression is an independent prognostic indicator of glioma. Oncotarget 8, 60987-61000.
Zhang, J., Stevens, M. F. and Bradshaw, T. D. (2012) Temozolomide: mechanisms of action, repair and resistance. Curr. Mol. Pharmacol. 5, 102-114.
Zhang, L., Guo, M., Li, J., Zheng, Y., Zhang, S., Xie, T. and Liu, B. (2015) Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer. Mol. Biosyst. 11, 2860-2866.

https://doi.org/10.4062/biomolther.2022.122